Clinical trial · Interventional
Brown Adipose Tissue Activity and Energy Metabolism in Cachexia
Brown Adipose Tissue Activity and Energy Metabolism in Cachexia Induced by Cancer or Chronic Disease
NCT02500004CI-TRIAL-00034126BAT-CachexiacompletedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To study BAT activity and energy metabolism in patients with cachexia induced by cancer or chronic disease.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cachexia | — | UNRESOLVED | — |
| Neoplasms | Neoplasm | ONTOLOGY_EXACT | 0.90 |
| Pancreatic Neoplasms | Pancreatic Neoplasm | ONTOLOGY_EXACT | 0.98 |
| Pulmonary Disease, Chronic Obstructive | — | UNRESOLVED | — |
Interventions
Interventions (7)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 18F-FDG PET-MRI-imaging | Radiation | — | UNRESOLVED |
| Abdominal subcutaneous adipose tissue biopsy | Procedure | — | UNRESOLVED |
| Accelerometry | Device | — | UNRESOLVED |
| Blood sampling | Procedure | — | UNRESOLVED |
| Double-labeled water | Other | — | UNRESOLVED |
| DXA scanning | Radiation | — | UNRESOLVED |
| Indirect calorimetry | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (5)
- type
- ACTIVE_COMPARATOR
- label
- Cachectic pancreatic cancer
- description
- Cachectic patients with pancreatic cancer BAT activity: 18F-FDG PET-MRI-imaging. Body composition: DXA scanning, D2O and MRI. Inflammatory and metabolic profile of adipose tissue: abdominal subcutaneous adipose tissue biopsy. Systemic inflammatory profile: blood sampling. Resting metabolic rate: indirect calorimetry. Physical activity level: accelerometry. Total daily energy expenditure: double-labeled water.
- interventionNames
- Radiation: 18F-FDG PET-MRI-imaging
- Radiation: DXA scanning
- Procedure: Abdominal subcutaneous adipose tissue biopsy
- Procedure: Blood sampling
- Other: Indirect calorimetry
- Device: Accelerometry
- Other: Double-labeled water
- type
- ACTIVE_COMPARATOR
- label
- Cachectic NSCLC
- description
- Cachectic patients with non-small cell lung cancer BAT activity: 18F-FDG PET-MRI-imaging. Body composition: DXA scanning, D2O and MRI. Inflammatory and metabolic profile of adipose tissue: abdominal subcutaneous adipose tissue biopsy. Systemic inflammatory profile: blood sampling. Resting metabolic rate: indirect calorimetry. Physical activity level: accelerometry. Total daily energy expenditure: double-labeled water.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 30 Years
Show eligibility criteria text
Inclusion Criteria: * Pancreatic cancer patients, or NSCLC cancer patients, or COPD patients * The diagnostic criterion for cachexia is unintentional weight loss more than 5% over the past 6 months or more than 2% in individuals with a body-mass index \< 20 kg/m2 and muscle wasting assessed by DXA; * Age ≥ 30 years; * Gender: male and female; * Caucasians. Exclusion Criteria: * Uncontrolled Diabetes Mellitus; * Patients with severe clotting disorder; * Patients with an active second malignancy; * Psychological unstable persons presumed unfit to perform the measurements, including claustrophobia; * Persons unable to lie or sit still for 1-2 hours; * Oxygen therapy; * Pregnant subjects;Subjects unable to undergo MRI (e.g. pacemaker; neurostimulator; implantable cardioverter-defibrillator (ICD) or leads; Foley bladder catheter; medication pump; cochlear or hearing implant; tattoos or other items that cannot be removed and include metal parts (for instance from operations in the past); metal splinter in the eye; vascular clips; denture, which contains magnets); * Subjects that received high doses of radiotherapeutic radiation of the neck and/or upper chest in their medical history; * Persons that received cervical or thoracic sympathectomy or have a nerve dysfunction which is likely to influence sympathetic nerves; * The use of medication that influences the sympathetic nerve system: ß-blockers, α-blockers, central anti-hypertensives, certain anti-depression drugs (MAO inhibitors, tricyclic anti-depressives), reserpine, cocaine, calciumblockers, labetalol, and certain tranquillizers (fenothiazines).
References
Publications (1)
- DERIVEDSanders K, Klooster K, Vanfleteren LEGW, Plasqui G, Dingemans AM, Slebos DJ, Schols AMWJ. Effect of Bronchoscopic Lung Volume Reduction in Advanced Emphysema on Energy Balance Regulation. Respiration. 2021 Feb 5:1-8. doi: 10.1159/000511920. Online ahead of print. PMID 33550302